On March 1, 2022 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "the Company") reported the status of acquisition of its own shares as stated below (Press release, Astellas, MAR 1, 2022, View Source [SID1234609201]). The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Particulars
Class of shares acquired: Common stock of the Company
Total number of shares acquired: 14,838,800 shares
Total amount of acquisition cost: 29,357,828,600 yen
Period of acquisition: From February 3, 2022 to February 28, 2022
Method of acquisition: Purchased on the Tokyo Stock Exchange
(Reference)
Details of the resolution at the meeting of the Board of Directors (announced on February 2, 2022)
- Class of shares to be acquired: Common stock of the Company
- Total number of shares to be acquired: Up to 29 million shares
(Ratio to the total number of shares outstanding
[excluding treasury stock]: 1.57%)
Accumulated Company’s own shares acquired through February 28, 2022, pursuant to the above board resolution
- Total number of shares acquired: 14,838,800 shares
- Total amount of acquisition cost: 29,357,828,600 yen